Evicenter
Imbruvica (ibrutinib) in Chronic lymphocytic leukemia and small lymphocytic lymphoma
Manufacturer
Pharmacyclics LLC; Janssen Biotech, Inc.
Prescribing information
Imbruvica (opens in a new tab)
Questions
58
Last updated

All questions

Safety: Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma

12 questions · 11 sources

Monitoring

Is a rise in lymphocytes on Imbruvica a sign of CLL progression?

Safety management

Do side effects resolve after an Imbruvica dose reduction (pooled analysis)?

Applies to Adults with previously untreated (first-line) CLL/SLL

Side effects

What are the most common side effects of Imbruvica in CLL/SLL?

Note: The percentages are from pooled data in adults with B-cell malignancies; the Prescribing Information sentence lists the most common adverse reactions in CLL/SLL without percentages.

What are the most common grade 3 or higher side effects of Imbruvica?

Applies to Adults with B-cell malignancies, including CLL/SLL (pooled label safety data)

How often do CLL patients stop or reduce Imbruvica because of side effects?

What are the long-term side effects of Imbruvica over 10 years (RESONATE-2)?

Applies to Adults with previously untreated (first-line) CLL/SLL

Note: Each percentage is the share of the 135 patients treated with Imbruvica who had the event at any time over up to 10 years of follow-up.

Do Imbruvica side effects change over 5 years of treatment (pooled CLL data)?

Note: The 1,284-patient long-term analysis, the source of the Grade 3 or greater hypertension rates, included patients with B-cell malignancies (warnings and precautions page); the rollover and follow-up pool of CLL/SLL patients is N=808.

What side effects occurred with Imbruvica vs chlorambucil (RESONATE-2)?

Applies to Adults with previously untreated (first-line) CLL/SLL

“Median duration of exposure was 17.4 months for IMBRUVICA® vs 7.1 months for chlorambucil1 IMBRUVICA® (n=135) Chlorambucil (n=132) Adverse Reaction All Grades (%) Grade 3 or Higher (%) All Grades (%) Grade 3 or Higher (%) Gastrointestinal disorders Diarrhea 42 4 17 0 Nausea 22 1 39 1 Constipation 16 1 16 0 Stomatitis* 14 1 4 1 Vomiting 13 0 20 1 Abdominal pain 13 3 11 1 Dyspepsia 11 0 2 0 Musculoskeletal and connective tissue disorders Musculoskeletal pain* 36 4 20 0 Arthralgia 16 1 7 1 Muscle spasms 11 0 5 0 General disorders and administration site conditions Fatigue 30 1 38 5 Peripheral edema 19 1 9 0 Pyrexia 17 0 14 2 Respiratory, thoracic, and mediastinal disorders Cough 22 0 15 0 Dyspnea 10 1 10 0 Skin and subcutaneous tissue disorders Rash* 21 4 12 2 Bruising* 19 0 7 0 Eye disorders Dry eye 17 0 5 0 Lacrimation increased 13 0 6 0 Vision blurred 13 0 8 0 Visual acuity reduced 11 0 2 0 Infections and infestations Upper respiratory tract infection 17 2 17 2 Skin infection* 15 2 3 1 Pneumonia* 14 8 7 4 Urinary tract infections 10 1 8 1 Vascular disorders Hypertension* 14 4 1 0 Nervous system disorders Headache 12 1 10 2 Dizziness 11 0 12 1 Investigations Weight decreased 10 0 12 0 Subjects with multiple events for a given ADR term are counted once only for each ADR term. The body system and individual ADR terms are sorted in descending frequency order in the IMBRUVICA® arm. Includes multiple ADR terms.” (opens the source at this quote in a new tab)

Note: Table columns are Imbruvica all grades, Imbruvica Grade 3 or higher, chlorambucil all grades, and chlorambucil Grade 3 or higher (% of patients).

What side effects occurred with Imbruvica vs ofatumumab in relapsed CLL (RESONATE)?

Applies to Adults with previously treated (relapsed or refractory) CLL/SLL

Note: Table columns are Imbruvica all grades, Imbruvica Grade 3 or higher (Grade 3 or 4 in the hematologic table), ofatumumab all grades, and ofatumumab Grade 3 or higher (% of patients).

What side effects occurred with Imbruvica plus rituximab vs FCR (E1912)?

Applies to Adults with previously untreated (first-line) CLL/SLL

Note: Table columns on the E1912 page are Imbruvica plus rituximab (IR) all grades, IR Grade 3 or higher, FCR all grades, and FCR Grade 3 or higher (% of patients). FCR is fludarabine, cyclophosphamide, and rituximab. The laboratory values are from Table 14 of the Prescribing Information, whose PDF text lists the row names of each section and then each column of values in the same order (Imbruvica plus rituximab all grades, Grade 3 or 4, then FCR all grades, Grade 3 or 4). The hematology rows of the E1912 page are not quoted because the page labels its second row Peripheral edema, where Table 14 lists platelets decreased with the same values.

What side effects occurred with Imbruvica plus obinutuzumab (iLLUMINATE)?

Applies to Adults with previously untreated (first-line) CLL/SLL

“Median duration of exposure was 29.3 months for IMBRUVICA® + obinutuzumab vs 5.1 months for chlorambucil + obinutuzumab1 IMBRUVICA® + obinutuzumab (n=113) chlorambucil + obinutuzumab (n=115) Adverse Reactions All Grades (%) Grade 3 or Higher (%) All Grades (%) Grade 3 or Higher (%) Blood and lymphatic system disorders Neutropenia* 48 39 64 48 Thrombocytopenia* 36 19 28 11 Anemia 17 4 25 8 Skin and subcutaneous tissue disorders Rash* 36 3 11 0 Bruising* 32 3 3 0 Gastrointestinal disorders Diarrhea 34 3 10 0 Constipation 16 0 12 1 Nausea 12 0 30 0 Musculoskeletal and connective tissue disorders Musculoskeletal pain* 33 1 23 3 Arthralgia 22 1 10 0 Muscle spasms 13 0 6 0 Respiratory, thoracic, and mediastinal disorders Cough 27 1 12 0 Injury, poisoning and procedural complications Infusion related reaction 25 2 58 8 Vascular disorders Hemorrhage* 25 1 9 0 Hypertension* 17 4 4 3 Infections and infestations Pneumonia* 16 9 9 4† Upper respiratory tract infection 14 1 6 0 Skin infection* 13 1 3 0 Urinary tract infection 12 3 7 1 Nasopharyngitis 12 0 3 0 Conjunctivitis 11 0 2 0 Metabolism and nutrition disorders Hyperuricemia 13 1 0 0 Cardiac disorders Atrial fibrillation 12 5 0 0 General disorders and administration site conditions Pyrexia 19 2 26 1 Fatigue 18 0 17 2 Peripheral edema 12 0 7 0 Psychiatric disorders Insomnia 12 0 4 0 The data are not an adequate basis for comparison of ADR rates between treatment arms. The body system and individual ADR terms are sorted in descending frequency order in the IMBRUVICA® arm. Includes multiple ADR terms. † Includes one event with a fatal outcome.” (opens the source at this quote in a new tab)

Note: Table columns are Imbruvica plus obinutuzumab all grades, Imbruvica plus obinutuzumab Grade 3 or higher, chlorambucil plus obinutuzumab all grades, and chlorambucil plus obinutuzumab Grade 3 or higher (% of patients).

What side effects occurred with Imbruvica plus bendamustine-rituximab (HELIOS)?

Applies to Adults with previously treated (relapsed or refractory) CLL/SLL

Note: Table columns are Imbruvica plus BR all grades, Imbruvica plus BR Grade 3 or higher, placebo plus BR all grades, and placebo plus BR Grade 3 or higher (% of patients). BR is bendamustine and rituximab.